| Abstrakt: |
One of the most serious conditions of CKD is anemia, and the high mortality rate is closely linked to the prognosis of CKD patients suffering anemia, predominantly brought about by a deficiency of the erythropoietin hormone as the major cause of emia. Loading erythropoietin alfa onto the surface of TiO2 NPs for the purpose of improving the efficiency of erythropoietin action in the blood and reducing the anemia state. Titanium dioxide NPs were created using the Sol–Gel method, and erythropoietin alpha was loaded onto titanium dioxide nanoparticles using an ultraviolet–visible study. X-ray diffraction (XRD), transmission electron microscopes (TEM), and energy dispersive X-rays (EDX) were used to diagnose titanium dioxide nanoparticles. A total of 60 rats were haphazard to be divided into 2 groups: the control group (12 rats) and the Anemia accompanied with CKD group (48 rats), which were divided into 4 groups: 12 rats not treated as group control, 12 rats treated with erythropoietin alfa, 12 rats treated with TiO2 NPs, and 12 rats treated with TiO2 NPs loaded with erythropoietin alfa. The mean size of the TiO2 NPs was 73.63 nm. The results have been a highly significant (p < 0.05) decrease in the levels of urea, creatinine, and ferritin and a highly significant (p < 0.05) increase in the levels of iron, folate, blood hemoglobin, RBCs, and erythropoietin in rats treated with TiO2 NPs loaded with erythropoietin alfa compared to the groups treated with erythropoietin alfa and TiO2 NPs. In our current study, it has been proven that TiO2 NPs loaded with erythropoietin alfa have a greater effect than TiO2 NPs and erythropoietin alfa. TiO2 nanoparticles may exhibit an effect on increasing the efficacy of erythropoietin alfa after being loaded, leading to a reduction in anemia disease. [ABSTRACT FROM AUTHOR] |
Full text from SpringerLink